INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
17/03/2024
Voltar para busca
Dado oficial do USPTO
RECIPHARM
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
17/03/2024
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
23/09/2010
Data de registro
29/11/2011
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/05/2023
Última transação
31/05/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
STOCKHOLM, SE
Examinador
MAKHDOOM,SAIMA
Unidade examinadora
L10
Localização atual
GENERIC WEB UPDATE
Descrição da marca
The mark consists of the word "RECIPHARM" appearing in turquoise with a turquoise flag above the letter "h" in the mark.
Titulares e representantes
Titulares
Recipharm AB (publ)
Recipharm AB (publ)
Representantes
Richard J. McKenna FOLEY & LARDNER LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsantibacterial pharmaceuticalsanti-diabetic pharmaceuticalsbalms for pharmaceutical purposescardiovascular pharmaceuticalsdermatological pharmaceutical productsdigestives for pharmaceutical purposesdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticalsinhaled pharmaceutical preparations for the treatment of respiratory diseases and disordersocular pharmaceuticalspharmaceutical anti-allergic preparations and substancespharmaceutical anti-allergic preparations and substancesanticoagulantsantidepressantsappetite suppressantspharmaceutical preparations for use in chemotherapypharmaceutical preparations for the treatment of heart rhythm disorderspharmaceutical preparations for the treatment of infectious diseasespharmaceutical preparations acting on the central nervous systempharmaceutical preparations and substances for the treatment of gastro-intestinal diseasespharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosispharmaceutical preparations for treating diabetespharmaceutical preparations for woundspharmaceutical preparations for use in urologypharmaceutical preparations for skin carepharmaceutical preparations for the treatment of kidney diseasespharmaceutical preparations and substances for the treatment of psychiatric diseases and disorderspharmaceutical preparations for the treatment of the thyroid gland
Classe 42
Medical research laboratory services; consultation services related to research in the field of development of surgical products; product development; development of medical products; and scientific and technological services and research and design relating thereto for medical purposesmedical and scientific research in the fields of cancer treatmentcardiovascular treatmenttreatment of infectious diseasestreatment of a wide variety of major medical human disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
07/02/2024
INPC
INVALIDATION PROCESSED
07/02/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
31/01/2024
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
31/05/2023
71AG
REGISTERED-SEC.71 ACCEPTED
31/05/2023
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
17/04/2023
PR71
POST REGISTRATION ACTION MAILED - SEC.71
02/11/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/10/2022
ES71
TEAS SECTION 71 RECEIVED
10/05/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
29/11/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/11/2020
RNWL
INTERNATIONAL REGISTRATION RENEWED
30/10/2020
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
12/10/2018
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
05/09/2018
INPC
INVALIDATION PROCESSED
05/09/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
17/08/2018
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
04/12/2017
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
04/12/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/12/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
16/11/2017
ES75
TEAS SECTION 71 & 15 RECEIVED
08/11/2017
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
29/11/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/08/2012
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/07/2012
FIMP
FINAL DISPOSITION PROCESSED
23/07/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
29/02/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
29/11/2011
GPNX
NOTIFICATION PROCESSED BY IB
20/11/2011
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/09/2011
PUBO
PUBLISHED FOR OPPOSITION
13/09/2011
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
24/08/2011
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
24/08/2011
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/08/2011
ALIE
ASSIGNED TO LIE
11/08/2011
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/07/2011
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/07/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/07/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/07/2011
RFNT
REFUSAL PROCESSED BY IB
29/01/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/01/2011
RFRR
REFUSAL PROCESSED BY MPU
11/01/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/01/2011
CNRT
NON-FINAL ACTION WRITTEN
09/01/2011
DOCK
ASSIGNED TO EXAMINER
31/12/2010
MAFR
APPLICATION FILING RECEIPT MAILED
23/11/2010
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/11/2010
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/11/2010
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RECIPHARM ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.